Chester County News and Community Website
WEST CHESTER, PA — Papyrus Therapeutics, Inc. and Oxford Biomedica plc (LSE: OXB), a leading gene and cell therapy group, announced the signing of a research collaboration agreement.
Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, announced the U.S. Food and Drug Administration (FDA) …
Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, announced the U.S. Food and Drug Administration (FDA) …
Read More
The U.S. Food and Drug Administration recently approved Tecartus (brexucabtagene autoleucel), a cell-based gene therapy for treatment of adult patients diagnosed with mantle cell lymphoma (MCL) who have not responded …
Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat the whole eye, today announced the decision to discontinue the …
Read More
MALVERN, PA — Ocugen, Inc., (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, announced the publication in Nature Gene Therapy …
Read More
EXTON, PA — Frontage Holdings Corporation, a contract research organization (“CRO”) providing integrated, science-driven, product development services, recently announced the expansion of its bioanalytical laboratories in Exton, PA, through its wholly-owned …
Read More
WASHINGTON, D.C. — This is a pivotal time in the field of gene therapy as the FDA continues its efforts to support innovators developing new medical products for Americans and …
Read More
MALVERN, PA — Ocugen, Inc., (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, reported financial highlights …
Read More
EXTON, PA — Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U.S. Food and Drug …
Read More